This report describes the case of a patient with severe thromboembolism associated with hypereosinophilic syndrome during the acute phase who was successfully treated with benralizumab, an anti-interleukin-5 receptor alpha antibody. Here, IL5RA is linked to hypereosinophilic syndrome.